Abstract
<p class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: justify;"><strong><em><span style="font-size: 8.0pt; font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-BoldItalic; mso-ansi-language: EN-US;" lang="EN-US">Introduction: </span></em></strong><em><span style="font-size: 8.0pt; font-family: Calibri-Italic; mso-hansi-font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-Italic; mso-ansi-language: EN-US;" lang="EN-US">The prescribing a drug without the indications for which the drug was originally approved by regulators is internationally known as prescribing “off-label”. </span></em><strong><em><span style="font-size: 8.0pt; font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-BoldItalic; mso-ansi-language: EN-US;" lang="EN-US">Objective</span></em></strong><em><span style="font-size: 8.0pt; font-family: Calibri-Italic; mso-hansi-font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-Italic; mso-ansi-language: EN-US;" lang="EN-US">: To describe the off-label therapy in diabetic retinopathy, reported international scientific literature, through an integrative bibliographical review. </span></em><strong><em><span style="font-size: 8.0pt; font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-BoldItalic; mso-ansi-language: EN-US;" lang="EN-US">Method</span></em></strong><em><span style="font-size: 8.0pt; font-family: Calibri-Italic; mso-hansi-font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-Italic; mso-ansi-language: EN-US;" lang="EN-US">: Integrative review by searching the Medline international database for review of manuscripts. </span></em><strong><em><span style="font-size: 8.0pt; font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-BoldItalic; mso-ansi-language: EN-US;" lang="EN-US">Results</span></em></strong><em><span style="font-size: 8.0pt; font-family: Calibri-Italic; mso-hansi-font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-Italic; mso-ansi-language: EN-US;" lang="EN-US">: A total 852 scientific productions were identified, and 37 studies were selected by contain information about the off-label therapy in diabetic retinopathy. </span></em><strong><em><span style="font-size: 8.0pt; font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-BoldItalic; mso-ansi-language: EN-US;" lang="EN-US">Conclusion</span></em></strong><em><span style="font-size: 8.0pt; font-family: Calibri-Italic; mso-hansi-font-family: Calibri-BoldItalic; mso-bidi-font-family: Calibri-Italic; mso-ansi-language: EN-US;" lang="EN-US">: The practice of off-label prescribing in diabetic retinopathy has benefits, and in some situations is the only treatment available.</span></em></p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
